‌

US Patent 7863274 Deuterium enriched analogues of tadalafil as PDE5 inhibitors

Patent 7863274 was granted and assigned to Concert Pharmaceuticals on January, 2011 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

Patent

Patent attributes

Current Assignee

Concert Pharmaceuticals

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

78632740

Patent Inventor Names

Roger Tung0

Date of Patent

January 4, 2011

Patent Application Number

117045550

Date Filed

February 8, 2007

Patent Citations Received

‌

US Patent 12116355 Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia

‌

US Patent 12071416 Prodrugs of 4-( (1R, 3S)-6-chloro-3-phenyl-2, 3-dihydro-1H-inden-1-yl)-1,2, 2-trimethylpiperazine and 4-( (1R, 3S)-6-chloro-3-(phenyl-D5)-2, 3-dihydro-1H-inden-1-yl)-2, 2-dimethyl-1 (methyl-D3) piperazine

Patent Primary Examiner

‌

James O. Wilson

Patent abstract

The present invention relates to derivatives of tadalafil represented by the formula:

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 7863274 Deuterium enriched analogues of tadalafil as PDE5 inhibitors

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API